PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ADHD medicine affects the brain's reward system

A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system

2012-11-09
(Press-News.org) A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system. The model makes it possible to understand the effect of the medicine and perhaps in the longer term to improve the development of medicine and dose determination. The new research results have been published in the Journal of Neurophysiology.

In Denmark approximately 2-3 per cent of school-age children satisfy diagnostic criteria for ADHD, and therefore it is crucial to know how the medicine works. With a new mathematical reconstruction of a tiny part of the brain region that registers reward and punishment, scientists from the University of Copenhagen are acquiring new knowledge about the effect of ADHD medicine. When reward and punishment signals run through the brain, the chemical dopamine is always involved.

"It has been discussed for years whether treating ADHD with Ritalin and similar drugs affects the reward system to any significant degree, simply because the dosage given to patients is so low. We are the first to show that some components of the dopamine signalling pathways are extremely sensitive to drugs like Ritalin. We have also developed a unified theory to describe the effect of such drugs on the dopamine signal," says Jakob Kisbye Dreyer, postdoctoral candidate at the Department of Neuroscience and Pharmacology, Faculty of Medical and Health Sciences, University of Copenhagen, where the model was developed.

He emphasises the importance of knowing exactly what happens during treatment with drugs like Ritalin. This is in order to develop better and more targeted medicine, as well as to understand the psychology underlying ADHD. The actions of human beings are motivated by an unconscious calculation of cost relative to expected gain. The scientists' results show that ADHD medicine specifically reduces signals about anticipated punishment.

Reward and punishment

In the brain, dopamine contributes to series of processes that control our behaviour. Actions such as eating, winning a competition, having sex or taking a narcotic drug increase dopamine release. Scientists think that dopamine helps motivate us to repeat actions that have previously been associated with reward.

"Control mechanisms in the brain help keep the dopamine signal in balance so we can register the tiny deviations that signal reward and punishment. We discovered while trying to describe these control mechanisms that our model can be used to examine the influence of Ritalin, for example, on the signal. Suddenly we could see that different pathways of the reward system are affected to different degrees by the medicine, and we could calculate at what dosage different parts of the signal would be changed or destroyed," says Jakob Kisbye Dreyer.

Different dosage, different effect

Drugs such as Ritalin can have paradoxical effects: high dosage increases the patient's activity while low dosage reduces it. Therefore it can be a laborious process to find the right dosage for a patient.

"We can explain this double effect using our theory. The dopamine signal in the part of the brain that controls our motor behaviour is only affected at a higher dose that the dose usually prescribed for treatment. Also, our model shows that the threshold between a clinically effective dose and too high a dose is very low. That may explain why the small individual differences between patients have a big impact on treatment," says Jakob Kisbye Dreyer.

In the long term, the scientists hope that their new insight will help doctors determine the correct dose for each patient. The model can also help us understand what signals in the brain affect not only ADHD, but schizophrenia, Parkinson's disease and drug abuse as well.

### Read the article in the Journal of Neurophysiology.

Contact

Postdoc Jakob Kisbye Dreyer
Department of Neuroscience and Pharmacology
Faculty of Health and Medical Sciences
Phone: +45 6080 9551
E-mail: jakobdr@sund.ku.dk


ELSE PRESS RELEASES FROM THIS DATE:

New mechanism of action for PARP inhibitors discovered

2012-11-09
PHILADELPHIA — New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has led to the identification of ways in which the patient population that might benefit from PARP inhibitors could be expanded. Yves Pommier, M.D., Ph.D., chief of the Laboratory of Molecular Pharmacology at the National Cancer Institute's Center for Cancer Research in Bethesda, Md., and colleagues reported these data in Cancer Research, a journal ...

Link found between child prodigies and autism

2012-11-09
COLUMBUS, Ohio - A new study of eight child prodigies suggests a possible link between these children's special skills and autism. Of the eight prodigies studied, three had a diagnosis of autism spectrum disorders. As a group, the prodigies also tended to have slightly elevated scores on a test of autistic traits, when compared to a control group. In addition, half of the prodigies had a family member or a first- or second-degree relative with an autism diagnosis. The fact that half of the families and three of the prodigies themselves were affected by autism is surprising ...

Study questions the relevance of SCIP benchmarks among CABG patients

2012-11-09
(Boston) – Cardiothoracic surgeons and endocrinologists from Boston Medical Center (BMC) have found that among patients undergoing coronary artery bypass graft (CABG) surgery, achieving Surgical Care Improvement Project (SCIP) benchmarks for glycemic control may be irrelevant when perioperative continuous insulin infusion protocols are implemented. These findings appear on-line in the Journal of Thoracic and Cardiovascular Surgery. Currently, 40 percent of all patients undergoing CABG suffer from diabetes, and this number is quickly rising. Traditionally these patients ...

Belatacept after a kidney transplant: Minor added benefit for certain patients

2012-11-09
Belatacept (trade name Nulojix®) has been approved since June 2011 to prevent a rejection reaction of the body to the donor organ (transplant) in adults who have received a kidney transplant. The Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG). The assessment showed an indication of a minor added benefit of belatacept in adults with transplants from donors who had been selected according to the so-called standard criteria. Serious side ...

Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors

2012-11-09
Researchers at Moffitt Cancer Center have identified metabolic signatures that may pave the way for personalized therapy in glioma, a type of tumor that starts in the brain. The study appears online in the October issue of Cancer Research, a publication of the American Association for Cancer Research. According to the authors, little has been known about the underlying metabolic alterations that may drive the growth of the most aggressive type of glioma, termed glioblastoma. "For the first time, we have described global metabolomic signatures in glioma," said study ...

Considerable added benefit of ipilimumab in advanced melanoma

2012-11-09
The humanized antibody ipilimumab (trade name Yervoy®) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means that the melanoma can no longer be removed by an operation or that metastases have formed. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, the drug offers major advantages with ...

University of Huddersfield physicist investigates the Big Bang particle

2012-11-09
Scientists at the University of Huddersfield are collaborating with experts at some of the world's leading research institutes in an attempt to unravel the mysteries of a particle that played a role in the creation of the universe. The existence of neutrinos and anti-neutrinos – particles that are almost massless and which travel at light speed from one side of the earth to the other – was confirmed more than 50 years ago. Scientists believe that they were created at the Big Bang and might hold the key to the nature of the universe. But they are light particles that ...

Vandetanib in thyroid cancer: No proof of added benefit

2012-11-09
Vandetanib (trade name Caprelsa®) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, because no data on patient-relevant outcomes for those patients for whom the drug is approved were presented by the drug manufacturer in its dossier. ...

UGR and Michael J. Fox Foundation take a step forward in the study of Parkinson's disease

2012-11-09
This press release is available in Spanish. During the past year, the research group TIC 218 at the Department of Signal Theory, Telematics and Communications attached to the University of Granada and the Andalusian Information Technology and Communications Center (CITIC) has implemented the methods for the detection and diagnosis of Alzheimer's disease, within the PPMI initiative of the Michael J. Fox foundation for the study of Parkinson's disease. In addition, other databases were used such as that of the Virgen de la Victoria Hospital, Málaga, Spain, and Virgen de ...

CHOP experts describe research in pediatric heart disease

2012-11-09
Physician-researchers from the Cardiac Center at The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions 2012 in Los Angeles. They described racial disparities in risk factors for sudden cardiac death, imaging modalities and novel approaches to assessing cardiac anomalies, ventricular assist device use, special considerations in syndromes in adult congenital heart disease, changes in immunosuppressive drugs after pediatric heart transplant, and many other topics. Children's ...

LAST 30 PRESS RELEASES:

NHS urged to offer single pill to all over-50s to prevent heart attacks and strokes

Australian researchers call for greater diversity in genomics

The pot is already boiling for 2% of the world’s amphibians: new study

A new way to predict cancer's spread? Scientists look at 'stickiness' of tumor cells

Prehistoric bone tool ‘factory’ hints at early development of abstract reasoning in human ancestors

Study: Vaping does not help US tobacco smokers quit

Insect populations are declining — and that is not a good thing

Scientists discover genes to grow bigger tomatoes and eggplants

Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease

Cancer screening 3 years after the onset of the COVID-19 pandemic

Trajectories of sleep duration, sleep onset timing, and continuous glucose monitoring in adults

Sports gambling and drinking behaviors over time

For better quantum sensing, go with the flow

Toxic environmental pollutants linked to faster aging and health risks in US adults

Jerome Morris voted AERA President-Elect; key members elected to AERA Council

Study reveals how agave plants survive extreme droughts

Aligning Science Across Parkinson’s (ASAP) launches a second funding opportunity to accelerate novel tool development to advance Parkinson's disease research

New study: Eating mangos daily shown to improve insulin sensitivity and blood glucose control

Highly radioactive nuclear waste – how to keep it from oblivion

Generations ‘sync’ up in rural ‘glades’ to boost technology use for health

Unveiling the mechanism of maintenance of replication and transcription in mitochondria

Pioneering research into brain cancer is awarded the world’s largest brain research prize, The Brain Prize

Concrete evidence: Japanese buildings absorb 14% of cement production's carbon footprint

New study examines how physics students perceive recognition

For some, childhood adversity can promote resilience to anxiety disorders

A sustainable iron catalyst for water oxidation in renewable energy

Cloud–radiation feedbacks found to be key to the diverse tropical pacific warming projections

Body image perceptions take shape from early childhood, psychologists reveal

Can long-term use of anti-inflammatory medications prevent dementia?

Review supports introducing small amounts of food allergens during early childhood

[Press-News.org] ADHD medicine affects the brain's reward system
A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system